Cangen and Dai Nippon Printing Co. Move Forward with Development of an Early Stage Lung Cancer Diagnostic
Complete the form below to unlock access to ALL audio articles.
Cangen Biotechnologies, Inc. and Dai Nippon Printing Co., Ltd. (DNP) of Japan have announced that they will move forward with a clinical trial phase of an early stage lung cancer diagnostic.
Based on successful first phase testing that utilized an assay technology combining proprietary technologies from each party, the assay was able to differentiate between normal and lung cancer samples. The 1000 patient sample study was performed in the United States at a publicly held third party CLIA certified laboratory.
Cangen and DNP will begin the clinical trial phase in early 2009 with FDA submission of the test expected by 2011. “As we move forward with this new biotechnology, we are excited about the prospect of being able to offer earlier lung cancer detection with greater accuracy,” said Cathy McDermott, RN, MPH, Vice President, Regulatory Affairs and Technical Development, Cangen Biotechnologies.
To accelerate the project, Cangen will receive a milestone payment as part of the Technical Collaboration Agreement with DNP initiated in March 2007, for its technical contribution to the collaboration.
Further development of the product may lead to additional milestone payments to Cangen toward the funding of a Phase 3 trial in the United States.
